UNSPSC 51152019: Butamisole hydrochloride

This classification denotes an antihelminthic agent with the molecular formula C15H19N3OS.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QGM18599H5, chemically known as propanamide, 2-methyl-n-(3-(2,3,5,6-tetrahydroimidazo(2,1-b)thizol-6-yl)phenyl)-, monohydrochloride, (-)- but generally known as butamisole hydrochloride, which bears US NIH Compound Identifier 166571. Most nations schedule butamisole hydrochloride under HS 29349990 and SITC 51579.

As of Q4 2014, BUTAMISOLE HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. Butamisole hydrochloride bears US NLM identifiers UMLS ID C0700565 and NCI Concept Code C79919. SMILES: CC(C)C(=O)NC1=CC=CC(=C1)C2CN3CCSC3=N2.CL.

UNSPSC 51152019 Butamisole hydrochloride is a Commodity code for a specific pharmaceutical active ingredient, but the recent state and local opportunities tagged under it show a significant mismatch with the code's nominal scope. The two posted opportunities — one from Seminole County, Florida procuring naloxone and drug deactivation systems, and one from the Texas Health and Human Services Commission gathering vendor intelligence on direct-to-manufacturer prescription programs — involve finished pharmaceutical products and pharmacy benefit program structure, not butamisole hydrochloride as an active pharmaceutical ingredient. The code shows minimal relevant recent activity aligned with its actual product definition, suggesting either sporadic demand for the ingredient itself at the state and local level or consistent misclassification of pharmaceutical procurement under this code designation.

The only geographically distinct jurisdictions in recent postings are Florida (Seminole County) and Texas (HHS Commission). Seminole County's IFB 60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023, solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the contract carries a two-year initial term with a one-year renewal option and requires E-Verify compliance, workers' compensation insurance, and potential FEMA funding with associated federal compliance obligations. The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, requested vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program designed to inform future formal procurement strategy but did not solicit specific products or commit to contract values. Given the code mismatch and the absence of solicitations for butamisole hydrochloride itself, this code warrants close monitoring rather than active pursuit at present.